Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111488 · ClinicalTrials.gov registry record · Phase 3
Guidant Microwave Ablation System for the Treatment of Atrial Fibrillation
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00111488 is a Phase 3 study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 200 participants.
The verdict
NCT00111488, a Phase 3 study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of the Randomized Study of Surgical Ablation with Microwave Energy for the Treatment of Atrial Fibrillation (RESOLVE-AF) trial is to determine the safety and effectiveness of the Guidant FLEX® Microwave Surgical Ablation System in the treatment of permanent atrial fibrillation (AF).
Interventions
- DEVICE Flex 4 and Generator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111488
The ClinicalTrials.gov registry entry for NCT00111488 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Flex 4 and Generator is the first listed.
NCT00111488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00111488 about?
NCT00111488 is a clinical study titled "Guidant Microwave Ablation System for the Treatment of Atrial Fibrillation". The purpose of the Randomized Study of Surgical Ablation with Microwave Energy for the Treatment of Atrial Fibrillation (RESOLVE-AF) trial is to determine the safety and effectiveness of the Guidant FLEX® Microwave Surgical Ablation System in the treatment of permanent atrial fibrillation (AF).
What is the current status of trial NCT00111488?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2005-06. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00111488?
The interventions under investigation include: Flex 4 and Generator (DEVICE).
Who is sponsoring clinical trial NCT00111488?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.